CAR T cell therapy: newer approaches to counter resistance and cost. Issue 4 (April 2020)

• Record Type: Journal Article
• Authors: Yadav, Rajesh Kumar; Ali, Asgar; Kumar, Santosh; Sharma, Alpana; Baghchi, Basab; Singh, Pritanjali; Das, Sushmita; Singh, Chandramani; Sharma, Sadhana
• Is Part Of: Heliyon. Volume 6:Issue 4(2020)
• Publication Date: 2020-04
• Subjects: Immunotherapy -- CAR T cells -- Tumor mutation burden -- Epigenetics -- Combination therapy -- Affordable -- Cell biology -- Immunology -- Genetics -- Proteins -- Biochemistry -- Molecular biology -- Cancer research -- Health sciences -- Oncology -- Clinical research; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2020.e03779
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: The genetically engineered Chimeric Antigen Receptor bearing T-cell (CAR T cell) therapy has been emerged as the new paradigm of cancer immunotherapy. However, recent studies have reported an increase in the number of relapsed haematological malignancies. This review provides newer insights into how the efficacy of CAR T cells might be increased by the application of new genome editing technologies, monitoring the complexity of tumor types and T cells sub-types. Next, tumor mutation burden along with tumormicroenvironment and epigenetic mechanisms of CAR T cell as well as tumor cell may play a vital role to tackle the cancer resistance mechanisms. These studies highlight the need to consider traditional cancer therapy in conjunction with CAR T cell therapy for relapsed or cases unresponsive to treatment. Of note, this therapy is highly expensive and requires multi-skill for successful implementation, which results in reduction of its accessibility/affordability to the patients. Here, we also propose a model for cost minimization of CAR T cell therapy by a collaboration of academia, hospitals and industry. Abstract : Immunotherapy, CAR T cells, Tumor mutation burden, Epigenetics, Combination therapy, Affordable; Cell biology; Immunology; Genetics; Proteins; Biochemistry; Molecular biology; Cancer research; Health sciences; Oncology; Clinical research